What labs are elevated in Guillain Barre?

1. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123–133. [PMC free article] [PubMed] [Google Scholar]

2. Asbury AK, Arnason BGW, Karp HR, McFarlin DE. Criteria for diagnosis of Guillain-Barré syndrome. Ann. Neurol. 1978;3:565–566. [PubMed] [Google Scholar]

3. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 1990;27:S21–S24. [PubMed] [Google Scholar]

4. Sejvar JJ, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599–612. [PubMed] [Google Scholar]

5. Hadden RD, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann. Neurol. 1998;44:780–788. [PubMed] [Google Scholar]

6. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388:717–727. [PubMed] [Google Scholar]

7. Van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in Guillain-Barré syndrome. Neurology. 2013;80:1650–1654. [PubMed] [Google Scholar]

8. Dominguez-Moreno R, et al. Mortalidad asociada al diagnostico de sindrome de Guillain-Barré en adultos ingresados en instituciones del sistema sanitario Mexicano [mortality associated with a diagnosis of Guillain-Barré syndrome in adults of Mexican health institutions] Rev. Neurol. 2014;58:4–10. [PubMed] [Google Scholar]

9. Dourado ME, Felix RH, da Silva WK, Queiroz JW, Jeronimo SM. Clinical characteristics of Guillain-Barré syndrome in a tropical country: a Brazilian experience. Acta Neurol. Scand. 2012;125:47–53. [PubMed] [Google Scholar]

10. Fokke C, et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137:33–43. [PubMed] [Google Scholar]

11. Doets AY, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141:2866–2877. [PubMed] [Google Scholar]

12. Ruts L, Drenthen J, Jacobs BC, van Doorn PA, Dutch Guillain-Barré syndrome Study Group Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology. 2010;74:1680–1686. [PubMed] [Google Scholar]

13. Kleyweg RP, van der Meche FG. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J. Neurol. Neurosurg. Psychiatry. 1991;54:957–960. [PMC free article] [PubMed] [Google Scholar]

14. Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J. Peripher. Nerv. Syst. 2009;14:310–315. [PubMed] [Google Scholar]

15. Principi N, Esposito S. Vaccine-preventable diseases, vaccines and Guillain-Barré syndrome. Vaccine. 2019;37:5544–5550. [PubMed] [Google Scholar]

16. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect. Dis. 2001;1:29–37. [PubMed] [Google Scholar]

17. Yoshikawa K, et al. Varied antibody reactivities and clinical relevance in anti-GQ1b antibody-related diseases. Neurol. Neuroimmunol. Neuroinflamm. 2018;5:e501. [PMC free article] [PubMed] [Google Scholar]

18. Jacobs BC, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51:1110–1115. [PubMed] [Google Scholar]

19. World Health Organization. Zika Situation Report 5 February 2016https://www.who.int/emergencies/zika-virus/situation-report/5-february-2016/en/ (2016).

20. Cao-Lormeau VM, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387:1531–1539. [PMC free article] [PubMed] [Google Scholar]

21. Parra B, et al. Guillain-Barré syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 2016;375:1513–1523. [PubMed] [Google Scholar]

22. Wilder-Smith A, et al. ZikaPLAN: Zika preparedness Latin American Network. Glob. Health Action. 2017;10:1398485. [PMC free article] [PubMed] [Google Scholar]

23. Jacobs BC, et al. International Guillain-Barre syndrome outcome study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barre syndrome. J. Peripher. Nerv. Syst. 2017;22:68–76. [PubMed] [Google Scholar]

24. Ropper, A. H., Wijdickr, E. F. M. & Truax, B. T. in Guillain-Barré Syndrome Ch. 12 (ed: Plum, F.) 155–160 (F.A. Davis Company, 1991).

25. Van den Berg B, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat. Rev. Neurol. 2014;10:469–482. [PubMed] [Google Scholar]

26. Ruts L, et al. Pain in Guillain-Barré syndrome: a long-term follow-up study. Neurology. 2010;75:1439–1447. [PubMed] [Google Scholar]

27. Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics. 2007;38:10–17. [PubMed] [Google Scholar]

28. Roodbol J, et al. Recognizing Guillain-Barré syndrome in preschool children. Neurology. 2011;76:807–810. [PubMed] [Google Scholar]

29. Yuki N, et al. Guillain-Barré syndrome associated with normal or exaggerated tendon reflexes. J. Neurol. 2012;259:1181–1190. [PubMed] [Google Scholar]

30. Ito M, et al. Bickerstaff’s brainstem encephalitis and fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J. Neurol. 2008;255:674–682. [PubMed] [Google Scholar]

31. Wakerley BR, et al. Guillain–Barré and Miller Fisher syndromes—new diagnostic classification. Nat. Rev. Neurol. 2014;10:537–544. [PubMed] [Google Scholar]

32. Sekiguchi Y, et al. How often and when fisher syndrome is overlapped by Guillain-Barré syndrome or Bickerstaff brainstem encephalitis? Eur. J. Neurol. 2016;23:1058–1063. [PubMed] [Google Scholar]

33. Uncini A, Yuki N. Sensory Guillain-Barré syndrome and related disorders: an attempt at systematization. Muscle Nerve. 2012;45:464–470. [PubMed] [Google Scholar]

34. Odaka M, et al. Bickerstaff’s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003;126:2279–2290. [PubMed] [Google Scholar]

35. Ito M, Matsuno K, Sakumoto Y, Hirata K, Yuki N. Ataxic Guillain-Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J. Neurol. Neurosurg. Psychiatry. 2011;82:294–299. [PubMed] [Google Scholar]

36. Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404. [PMC free article] [PubMed] [Google Scholar]

37. Van den Berg B, et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology. 2014;82:491–497. [PubMed] [Google Scholar]

38. Vellozzi C, Iqbal S, Broder K. Guillain-Barré syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin. Infect. Dis. 2014;58:1149–1155. [PubMed] [Google Scholar]

39. Thornton CA, Latif AS, Emmanuel JC. Guillain-Barré syndrome associated with human immunodeficiency virus infection in Zimbabwe. Neurology. 1991;41:812–815. [PubMed] [Google Scholar]

40. Islam B, et al. Guillain-Barré syndrome following varicella-zoster virus infection. Eur. J. Clin. Microbiol. Infect. Dis. 2018;37:511–518. [PubMed] [Google Scholar]

41. Carod-Artal FJ, Wichmann O, Farrar J, Gascon J. Neurological complications of dengue virus infection. Lancet Neurol. 2013;12:906–919. [PubMed] [Google Scholar]

42. Wielanek AC, Monredon JD, Amrani ME, Roger JC, Serveaux JP. Guillain-Barré syndrome complicating a Chikungunya virus infection. Neurology. 2007;69:2105–2107. [PubMed] [Google Scholar]

43. Cornblath DR, McArthur JC, Kennedy PG, Witte AS, Griffin JW. Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann. Neurol. 1987;21:32–40. [PubMed] [Google Scholar]

44. Schonberger LB, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am. J. Epidemiol. 1979;110:105–123. [PubMed] [Google Scholar]

45. Burwen DR, et al. Evaluation of Guillain-Barré syndrome among recipients of influenza vaccine in 2000 and 2001. Am. J. Prev. Med. 2010;39:296–304. [PubMed] [Google Scholar]

46. Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barré syndrome in the United States, 1979–1980 and 1980–1981: lack of an association with influenza vaccination. JAMA. 1982;248:698–700. [PubMed] [Google Scholar]

47. Lasky T, et al. The Guillain-Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N. Engl. J. Med. 1998;339:1797–1802. [PubMed] [Google Scholar]

48. Juurlink DN, et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch. Intern. Med. 2006;166:2217–2221. [PubMed] [Google Scholar]

49. Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr. Neurol. Neurosci. Rep. 2018;18:63. [PubMed] [Google Scholar]

50. Hiew FL, Rajabally YA. Malignancy in Guillain-Barré syndrome: a twelve-year single-center study. J. Neurol. Sci. 2017;375:275–278. [PubMed] [Google Scholar]

51. Rudant J, et al. Surgery and risk of Guillain-Barré syndrome: a French nationwide epidemiologic study. Neurology. 2018;91:e1220–e1227. [PubMed] [Google Scholar]

52. Ho TW, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118:597–605. [PubMed] [Google Scholar]

53. Kuijf ML, et al. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J. Neurol. Sci. 2005;239:37–44. [PubMed] [Google Scholar]

54. Uchibori A, Gyohda A, Chiba A. Ca2+-dependent anti-GQ1b antibody in GQ1b-seronegative Fisher syndrome and related disorders. J. Neuroimmunol. 2016;298:172–177. [PubMed] [Google Scholar]

55. Guillain G. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquode cephalo-rachidien sans reaction cellulaire: remarques sur les caracteres cliniques et graphiques des reflexes tendineux [radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes] Bell. Mem. Soc. Med. Paris. 1916;40:1462–1470. [PubMed] [Google Scholar]

56. Wong AH, et al. Cytoalbuminologic dissociation in Asian patients with Guillain-Barré and Miller Fisher syndromes. J. Peripher. Nerv. Syst. 2015;20:47–51. [PubMed] [Google Scholar]

57. Vucic S, Cairns KD, Black KR, Chong PS, Cros D. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin. Neurophysiol. 2004;115:2329–2335. [PubMed] [Google Scholar]

58. Meulstee J, van der Meche F, Dutch Guillain-Barré Study Group Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 1995;59:482–486. [PMC free article] [PubMed] [Google Scholar]

59. Berciano J, et al. Proximal nerve lesions in early Guillain-Barré syndrome: implications for pathogenesis and disease classification. J. Neurol. 2017;264:221–236. [PubMed] [Google Scholar]

60. Kuwabara S, Sekiguchi Y, Misawa S. Electrophysiology in Fisher syndrome. Clin. Neurophysiol. 2017;128:215–219. [PubMed] [Google Scholar]

61. Rajabally YA, Durand MC, Mitchell J, Orlikowski D, Nicolas G. Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice? J. Neurol. Neurosurg. Psychiatry. 2015;86:115–119. [PubMed] [Google Scholar]

62. Uncini A, Kuwabara S. The electrodiagnosis of Guillain-Barré syndrome subtypes: where do we stand? Clin. Neurophysiol. 2018;129:2586–2593. [PubMed] [Google Scholar]

63. Van den Bergh Peter Y. K., Piéret Françoise, Woodard John L., Attarian Shahram, Grapperon Aude-Marie, Nicolas Guillaume, Brisset Marion, Cassereau Julien, Rajabally Yusuf A., Van Parijs Vinciane, Verougstraete Donatienne, Jacquerye Philippe, Raymackers Jean-Marc, Redant Céline, Michel Claure, Delmont Emilien. Guillain-BarrÉ syndrome subtype diagnosis: A prospective multicentric European study. Muscle & Nerve. 2018;58(1):23–28. [PubMed] [Google Scholar]

64. Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain-Barré syndrome: a critical revision and the need for an update. Clin. Neurophysiol. 2012;123:1487–1495. [PubMed] [Google Scholar]

65. Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology. 1996;47:813–817. [PubMed] [Google Scholar]

66. Yikilmaz A, et al. Magnetic resonance imaging of childhood Guillain-Barré syndrome. Childs Nerv. Syst. 2010;26:1103–1108. [PubMed] [Google Scholar]

67. Elrick MJ, et al. Clinical subpopulations in a sample of North American children diagnosed with acute flaccid myelitis, 2012–2016. JAMA Pediatr. 2018;173:134–139. [PMC free article] [PubMed] [Google Scholar]

68. Hopkins SE, Elrick MJ, Messacar K. Acute flaccid myelitis—keys to diagnosis, questions about treatment, and future directions. JAMA Pediatr. 2018;173:117–118. [PubMed] [Google Scholar]

69. Maloney JA, et al. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. AJNR Am. J. Neuroradiol. 2015;36:245–250. [PMC free article] [PubMed] [Google Scholar]

70. Gallardo E, et al. Spinal nerve involvement in early Guillain-Barré syndrome: a clinico-electrophysiological, ultrasonographic and pathological study. Clin. Neurophysiol. 2015;126:810–819. [PubMed] [Google Scholar]

71. Razali SNO, et al. Serial peripheral nerve ultrasound in Guillain-Barré syndrome. Clin. Neurophysiol. 2016;127:1652–1656. [PubMed] [Google Scholar]

72. Vereninging Spierziekten Nederland, Nederlandse Vereniging voor Neurologie & Nederlandse Vereniging van Revalidatieartsen [Dutch Association of Muscular Diseases & Dutch Society of Rehabilitation Specialists]. in Multidisciplinaire richtlijn Guillain-Barré syndroom [Multidisciplinary guideline Guillain-Barré syndrome]https://www.spierziekten.nl/fileadmin/user_upload/VSN/documenten/Hulpverleners_overig/R030-RichtlijnGBSherdruk2011metbijlagen.pdf (2011).

73. Mehta S. Neuromuscular disease causing acute respiratory failure. Respir. Care. 2006;51:1016–1021. [PubMed] [Google Scholar]

74. Walgaard C, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann. Neurol. 2010;67:781–787. [PubMed] [Google Scholar]

75. Walgaard C, et al. Tracheostomy or not: prediction of prolonged mechanical ventilation in Guillain–Barré syndrome. Neurocrit. Care. 2017;26:6–13. [PMC free article] [PubMed] [Google Scholar]

76. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 2014;9:CD002063. [PMC free article] [PubMed] [Google Scholar]

77. Chevret S. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 2017;2:CD001798. [PMC free article] [PubMed] [Google Scholar]

78. Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics. 2005;116:8–14. [PubMed] [Google Scholar]

79. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann. Neurol. 1997;41:298–306. [PubMed] [Google Scholar]

80. Verboon C, van Doorn PA, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 2017;88:346–352. [PubMed] [Google Scholar]

81. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 2012;7:CD001798. [PubMed] [Google Scholar]

82. Hughes RA, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130:2245–2257. [PubMed] [Google Scholar]

83. Van Koningsveld R, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet. 2004;363:192–196. [PubMed] [Google Scholar]

84. Islam MB, et al. Small volume plasma exchange for Guillain-Barré syndrome in resource poor settings: a safety and feasibility study. Pilot Feasibility Stud. 2017;3:40. [PMC free article] [PubMed] [Google Scholar]

85. Overell JR, Hseih S-T, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaff’s brainstem encephalitis and related disorders. Cochrane Database Syst. Rev. 2007;1:CD004761. [PMC free article] [PubMed] [Google Scholar]

86. Verboon C, et al. Current treatment practice of Guillain-Barré syndrome. Neurology. 2019;93:e59–e76. [PubMed] [Google Scholar]

87. Tomimatsu T, et al. Guillain-Barré syndrome after trivalent influenza vaccination during pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2016;201:225–226. [PubMed] [Google Scholar]

88. Pacheco LD, Saad AF, Hankins GD, Chiosi G, Saade G. Guillain-Barré syndrome in pregnancy. Obstet. Gynecol. 2016;128:1105–1110. [PubMed] [Google Scholar]

89. Branch DW, Porter TF, Paidas MJ, Belfort MA, Gonik B. Obstetric uses of intravenous immunoglobulin: successes, failures, and promises. J. Allergy Clin. Immunol. 2001;108:S133–S138. [PubMed] [Google Scholar]

90. El-Bayoumi MA, et al. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain-Barré syndrome: a randomized study. Crit. Care. 2011;15:R164. [PMC free article] [PubMed] [Google Scholar]

91. Michon B, et al. Complications of apheresis in children. Transfusion. 2007;47:1837–1842. [PubMed] [Google Scholar]

92. Kannan Kanikannan MA, et al. Simple bedside predictors of mechanical ventilation in patients with Guillain-Barre syndrome. J. Crit. Care. 2014;29:219–223. [PubMed] [Google Scholar]

93. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch. Neurol. 2001;58:893–898. [PubMed] [Google Scholar]

94. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet. 1978;312:750–753. [PubMed] [Google Scholar]

95. Dhar R, Stitt L, Hahn AF. The morbidity and outcome of patients with Guillain-Barré syndrome admitted to the intensive care unit. J. Neurol. Sci. 2008;264:121–128. [PubMed] [Google Scholar]

96. Oczko-Walker M, Manousakis G, Wang S, Malter JS, Waclawik AJ. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency. J. Clin. Neuromuscul. Dis. 2010;12:55–61. [PubMed] [Google Scholar]

97. Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet. 1997;350:1747. [PubMed] [Google Scholar]

98. Walgaard C, et al. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial. J. Peripher. Nerv. Syst. 2018;23:210–215. [PubMed] [Google Scholar]

99. Van den Berg B, Storm EF, Garssen MJP, Blomkwist-Markens PH, Jacobs BC. Clinical outcome of Guillain-Barré syndrome after prolonged mechanical ventilation. J. Neurol. Neurosurg. Psychiatry. 2018;89:949–954. [PubMed] [Google Scholar]

100. Walgaard C, et al. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology. 2011;76:968–975. [PMC free article] [PubMed] [Google Scholar]

101. Soysal A, et al. Clinico-electrophysiological findings and prognosis of Guillain-Barré syndrome—10 years’ experience. Acta Neurol. Scand. 2011;123:181–186. [PubMed] [Google Scholar]

102. Bersano A, et al. Long term disability and social status change after Guillain-Barré syndrome. J. Neurol. 2006;253:214–218. [PubMed] [Google Scholar]

103. Forsberg A, Press R, Holmqvist LW. Residual disability 10 years after falling ill in Guillain-Barré syndrome: a prospective follow-up study. J. Neurol. Sci. 2012;317:74–79. [PubMed] [Google Scholar]

104. Hughes RA, et al. Supportive care for patients with Guillain-Barré syndrome. Arch. Neurol. 2005;62:1194–1198. [PubMed] [Google Scholar]

105. Davidson I, Wilson C, Walton T, Brissenden S. Physiotherapy and Guillain-Barré syndrome: results of a national survey. Physiotherapy. 2009;95:157–163. [PubMed] [Google Scholar]

106. Simatos Arsenault N, Vincent P-O, Yu BHS, Bastien R, Sweeney A. Influence of exercise on patients with Guillain-Barré syndrome: a systematic review. Physiother. Can. 2016;68:367–376. [PMC free article] [PubMed] [Google Scholar]

107. Garssen MP, Van Koningsveld R, Van Doorn PA. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barré syndrome. J. Neurol. 2006;253:1143–1146. [PubMed] [Google Scholar]

108. Merkies IS, et al. Fatigue in immune-mediated polyneuropathies. Neurology. 1999;53:1648–1654. [PubMed] [Google Scholar]

109. Garssen MPJ, et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP. Neurology. 2004;63:2393–2395. [PubMed] [Google Scholar]

110. Bernsen RA, de Jager AE, Kuijer W, van der Meche FG, Suurmeijer TP. Psychosocial dysfunction in the first year after Guillain-Barré syndrome. Muscle Nerve. 2010;41:533–539. [PubMed] [Google Scholar]

111. Wang Y, et al. IgG-degrading enzyme of Streptococcus pyogenes (IdeS) prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barré syndrome. Exp. Neurol. 2017;291:134–140. [PubMed] [Google Scholar]

112. Misawa S, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018;17:519–529. [PubMed] [Google Scholar]

113. Wakerley BR, Yuki N. Mimics and chameleons in Guillain-Barré and Miller Fisher syndromes. Pract. Neurol. 2015;15:90–99. [PubMed] [Google Scholar]

114. Wakerley BR, et al. Clinical classification of 103 Japanese patients with Guillain-Barre syndrome. J. Neurol. Sci. 2016;369:43–47. [PubMed] [Google Scholar]

115. Hiew FL, Ramlan R, Viswanathan S, Puvanarajah S. Guillain-Barré syndrome, variants & forms fruste: reclassification with new criteria. Clin. Neurol. Neurosurg. 2017;158:114–118. [PubMed] [Google Scholar]

116. Blum S, Reddel S, Spies J, McCombe P. Clinical features of patients with Guillain-Barré syndrome at seven hospitals on the East Coast of Australia. J. Peripher. Nerv. Syst. 2013;18:316–320. [PubMed] [Google Scholar]

117. Peric S, et al. Clinical and epidemiological features of Guillain-Barré syndrome in the western Balkans. J. Peripher. Nerv. Syst. 2014;19:317–321. [PubMed] [Google Scholar]

118. Zhang G, et al. Subtypes and prognosis of Guillain-Barré syndrome in Southwest China. PLOS ONE. 2015;10:e0133520. [PMC free article] [PubMed] [Google Scholar]

119. Mitsui Y, et al. A multicentre prospective study of Guillain-Barré syndrome in Japan: a focus on the incidence of subtypes. J. Neurol. Neurosurg. Psychiatry. 2015;86:110–114. [PubMed] [Google Scholar]

120. Ishaque T, et al. High mortality from Guillain-Barré syndrome in Bangladesh. J. Peripher. Nerv. Syst. 2017;22:121–126. [PubMed] [Google Scholar]

Page 2

Nature Reviews. Neurology

PMC full text:

Copyright/LicenseRequest permission to reuse

Copyright © The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Important complications of Guillain–Barré syndrome